Erratum: HIF-1 regulates CD47 expression in breast cancer cells to promote evasion of phagocytosis and maintenance of cancer stem cells (Proc. Natl. Acad. Sci. U.S.A. (2015) 112 (E6215–E6223) DOI:10.1073/pnas.1520032112);HIF-1 regulates CD47 expression in breast cancer cells to promote evasion of phagocytosis and maintenance of cancer stem cells

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 45, 2015, Pages E6215-E6223

  Zhang, Huimin ^a,b   Lu, Haiquan ^b   Xiang, Lisha ^b   Bullen, John W ^b   Zhang, Chuanzhao ^b   Samanta, Debangshu ^b   Gilkes, Daniele M ^b   He, Jianjun ^a   Semenza, Gregg L ^b  

^a THE FIRST AFFILIATED HOSPITAL OF XI AN JIAOTONG UNIVERSITY   (China)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1; CD47 ANTIGEN; CD47 PROTEIN, HUMAN; LUCIFERASE; PRIMER DNA; SMALL INTERFERING RNA;

BONE MARROW DERIVED MACROPHAGE; BREAST CANCER; BREAST CANCER CELL LINE; CANCER STEM CELL; CD47 GENE; CONFERENCE PAPER; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; MORTALITY; PHAGOCYTOSIS; PHENOTYPE; PRIORITY JOURNAL; ANALYSIS OF VARIANCE; BREAST TUMOR; CHROMATIN IMMUNOPRECIPITATION; DRUG EFFECTS; FEMALE; GENE EXPRESSION REGULATION; GENETICS; IMMUNOBLOTTING; METABOLISM; PHYSIOLOGY; REAL TIME POLYMERASE CHAIN REACTION; TUMOR CELL LINE; TUMOR ESCAPE;

ANALYSIS OF VARIANCE; ANTIGENS, CD47; BREAST NEOPLASMS; CELL LINE, TUMOR; CHROMATIN IMMUNOPRECIPITATION; DNA PRIMERS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; IMMUNOBLOTTING; LUCIFERASES; NEOPLASTIC STEM CELLS; PHAGOCYTOSIS; REAL-TIME POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; TUMOR ESCAPE;

EID: 84946751807     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.2418194121     Document Type: Erratum

References (57)

1. Vaupel P, Höckel M, Mayer A (2007) Detection and characterization of tumor hypoxia using pO2 histography. Antioxid Redox Signal 9(8):1221-1235.
2. Semenza GL (2015) The hypoxic tumor microenvironment: A driving force for breast cancer metastasis. Biochim Biophys Acta, 10.1016/j.bbamcr.2015.05.036.
3. Schito L, et al. (2012) Hypoxia-inducible factor 1-dependent expression of plateletderived growth factor B promotes lymphatic metastasis of hypoxic breast cancer cells. Proc Natl Acad Sci USA 109(40):E2707-E2716.
4. Liao D, Corle C, Seagroves TN, Johnson RS (2007) Hypoxia-inducible factor-1α is a key regulator of metastasis in a transgenic model of cancer initiation and progression. Cancer Res 67(2):563-572.
5. Zhang H, et al. (2012) HIF-1-dependent expression of angiopoietin-like 4 and L1CAMmediates vascular metastasis of hypoxic breast cancer cells to the lungs. Oncogene 31(14):1757-1770.
6. Hiraga T, Kizaka-Kondoh S, Hirota K, Hiraoka M, Yoneda T (2007) Hypoxia and hypoxia-inducible factor-1 expression enhance osteolytic bone metastases of breast cancer. Cancer Res 67(9):4157-4163.
7. Dunn LK, et al. (2009) Hypoxia and TGF-β drive breast cancer bone metastases through parallel signaling pathways in tumor cells and the bone microenvironment. PLoS One 4(9):e6896.
8. Chaturvedi P, et al. (2013) Hypoxia-inducible factor-dependent breast cancer-mesenchymal stem cell bidirectional signaling promotes metastasis. J Clin Invest 123(1):189-205.
9. Chaturvedi P, Gilkes DM, Takano N, Semenza GL (2014) Hypoxia-inducible factordependent signaling between triple-negative breast cancer cells and mesenchymal stem cells promotes macrophage recruitment. Proc Natl Acad Sci USA 111(20): E2120-E2129.
10. Gilkes DM, et al. (2014) Hypoxia-inducible factors mediate coordinated RhoA-ROCK1 expression and signaling in breast cancer cells. Proc Natl Acad Sci USA 111(3): E384-E393.
11. Erler JT, et al. (2006) Lysyl oxidase is essential for hypoxia-induced metastasis. Nature 440(7088):1222-1226.
12. Wong CC, et al. (2011) Hypoxia-inducible factor 1 is a master regulator of breast cancer metastatic niche formation. Proc Natl Acad Sci USA 108(39):16369-16374.
13. Gilkes DM, et al. (2013) Collagen prolyl hydroxylases are essential for breast cancer metastasis. Cancer Res 73(11):3285-3296.
14. Gilkes DM, et al. (2013) Procollagen lysyl hydroxylase 2 is essential for hypoxia-induced breast cancer metastasis. Mol Cancer Res 11(5):456-466.
15. Wang T, et al. (2014) Hypoxia-inducible factors and RAB22A mediate formation of microvesicles that stimulate breast cancer invasion and metastasis. Proc Natl Acad Sci USA 111(31):E3234-E3242.
16. Erler JT, et al. (2009) Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. Cancer Cell 15(1):35-44.
17. Favaro E, Lord S, Harris AL, Buffa FM (2011) Gene expression and hypoxia in breast cancer. Genome Med 3(8):55.
18. Samanta D, Gilkes DM, Chaturvedi P, Xiang L, Semenza GL (2014) Hypoxia-inducible factors are required for chemotherapy resistance of breast cancer stem cells. Proc Natl Acad Sci USA 111(50):E5429-E5438.
19. Conley SJ, et al. (2012) Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia. Proc Natl Acad Sci USA 109(8):2784-2789.
20. Xiang L, et al. (2014) Hypoxia-inducible factor 1 mediates TAZ expression and nuclear localization to induce the breast cancer stem cell phenotype. Oncotarget 5(24): 12509-12527.
21. Xiang L, et al. (2015) HIF-1α and TAZ serve as reciprocal co-Activators in human breast cancer cells. Oncotarget 6(14):11768-11778.
22. Mathieu J, et al. (2011) HIF induces human embryonic stem cell markers in cancer cells. Cancer Res 71(13):4640-4652.
23. Hatfield SM, et al. (2015) Immunological mechanisms of the antitumor effects of supplemental oxygenation. Sci Transl Med 7(277):277ra30.
24. Noman MZ, et al. (2015) Hypoxia: A key player in anti-Tumor immune response. Am J Physiol Cell Physiol, 10.1152/ajpcell.00207.2015.
25. Chao MP, Majeti R, Weissman IL (2012) Programmed cell removal: A new obstacle in the road to developing cancer. Nat Rev Cancer 12(1):58-67.
26. Kershaw MH, SmythMJ (2013) Immunology. Making macrophages eat cancer. Science 341(6141):41-42.
27. Gardai SJ, et al. (2005) Cell-surface calreticulin initiates clearance of viable or apoptotic cells through trans-Activation of LRP on the phagocyte. Cell 123(2):321-334.
28. Chao MP, et al. (2010) Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47. Sci Transl Med 2(63):63ra94.
29. Baccelli I, et al. (2013) Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay. Nat Biotechnol 31(6):539-544.
30. Weigelt B, Reis-Filho JS (2009) Histological and molecular types of breast cancer: Is there a unifying taxonomy? Nat Rev Clin Oncol 6(12):718-730.
31. Lee K, et al. (2009) Acriflavine inhibits HIF-1 dimerization, tumor growth, and vascularization. Proc Natl Acad Sci USA 106(42):17910-17915.
32. Semenza GL, et al. (1996) Hypoxia response elements in the aldolase A, enolase 1, and lactate dehydrogenase A gene promoters contain essential binding sites for hypoxiainducible factor 1. J Biol Chem 271(51):32529-32537.
33. Chan KS, et al. (2009) Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells. Proc Natl Acad Sci USA 106(33):14016-14021.
34. Lee TK, et al. (2014) Blockade of CD47-mediated cathepsin S/protease-Activated receptor 2 signaling provides a therapeutic target for hepatocellular carcinoma. Hepatology 60(1):179-191.
35. Cioffi M, et al. (2015) Inhibition of CD47 effectively targets pancreatic cancer stem cells via dual mechanisms. Clin Cancer Res 21(10):2325-2337.
36. Lo J, et al. (2015) Nuclear factor κ B-mediated CD47 up-regulation promotes sorafenib resistance and its blockade synergizes the effect of sorafenib in hepatocellular carcinoma in mice. Hepatology 62(2):534-545.
37. Dontu G, et al. (2003) In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev 17(10):1253-1270.
38. Ginestier C, et al. (2007) ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 1(5):555-567.
39. Cancer Genome Atlas Network (2012) Comprehensive molecular portraits of human breast tumours. Nature 490(7418):61-70.
40. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100(7): 3983-3988.
41. Krishnamachary B, et al. (2012) Hypoxia regulates CD44 and its variant isoforms through HIF-1α in triple negative breast cancer. PLoS One 7(8):e44078.
42. Ringnér M, Fredlund E, Häkkinen J, Borg A, Staaf J (2011) GOBO: Gene expressionbased outcome for breast cancer online. PLoS One 6(3):e17911.
43. Györffy B, et al. (2010) An online survival analysis tool to rapidly assess the effect of 22, 277 genes on breast cancer prognosis using microarray data of 1, 809 patients. Breast Cancer Res Treat 123(3):725-731.
44. Jaiswal S, et al. (2009) CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell 138(2):271-285.
45. Majeti R, et al. (2009) CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell 138(2):286-299.
46. Willingham SB, et al. (2012) The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc Natl Acad Sci USA 109(17):6662-6667.
47. Sitkovsky MV (2009) T regulatory cells: Hypoxia-Adenosinergic suppression and redirection of the immune response. Trends Immunol 30(3):102-108.
48. Baccelli I, et al. (2014) Co-expression of MET and CD47 is a novel prognosticator for survival of luminal breast cancer patients. Oncotarget 5(18):8147-8160.
49. Hoffmann PR, et al. (2001) Phosphatidylserine (PS) induces PS receptor-mediated macropinocytosis and promotes clearance of apoptotic cells. J Cell Biol 155(4): 649-659.
50. Ogden CA, et al. (2001) C1q and mannose binding lectin engagement of cell surface calreticulin and CD91 initiates macropinocytosis and uptake of apoptotic cells. J Exp Med 194(6):781-795.
51. Wu X, Liu X, Zhu X, Tang C (2007) Hypoxic preconditioning induces delayed cardioprotection through p38 MAPK-mediated calreticulin upregulation. Shock 27(5): 572-577.
52. Liu X, et al. (2015) CD47 blockade triggers T cell-mediated destruction of immunogenic tumors. Nat Med 21(10):1209-1215.
53. Pennacchietti S, et al. (2003) Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 3(4):347-361.
54. Lu H, et al. (2015) Chemotherapy triggers HIF-1-dependent glutathione synthesis and copper chelation that induces the breast cancer stem cell phenotype. Proc Natl Acad Sci USA 112(33):E4600-E4609.
55. Brown EJ, Frazier WA (2001) Integrin-Associated protein (CD47) and its ligands. Trends Cell Biol 11(3):130-135.
56. Xiang L, et al. (2014) Ganetespib blocks HIF-1 activity and inhibits tumor growth, vascularization, stem cell maintenance, invasion, and metastasis in orthotopic mouse models of triple-negative breast cancer. J Mol Med (Berl) 92(2):151-164.
57. Chia SK, et al. (2012) A 50-gene intrinsic subtype classifier for prognosis and prediction of benefit from adjuvant tamoxifen. Clin Cancer Res 18(16):4465-4472.